Milestone Pharmaceuticals faces an FDA setback for its PSVT nasal spray. The company coordinates with regulatory authorities to resolve CRL issues.

TD Cowen downgraded Milestone Pharmaceuticals (MIST) to Hold from Buy and suspended the firm’s price target after Milestone ...

The Food and Drug Administration (FDA) has issued a Complete Response Letter to Milestone Pharmaceuticals regarding the New Drug Application (NDA) for ...

H.C. Wainwright lowered the firm’s price target on Milestone Pharmaceuticals (MIST) to $10 from $25 and keeps a Buy rating on the shares after ...

Joe Oliveto, President and CEO of Milestone Pharmaceuticals, expressed disappointment over the CRL but reaffirmed the company’s commitment to CARDAMYST as a potential novel treatment for paroxysmal ...

Cardiology drug and device makers will be back in the spotlight this weekend as the annual scientific meeting of the American College of Cardiology gets underway in Chicago.

(NASDAQ:MIST) shares plummeted 60% following a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) concerning its New Drug Application (NDA) for CARDAMYST™ (etripamil) ...

The facility changed ownership during the review of the NDA. “We are deeply disappointed by the CRL but remain committed to the potential of CARDAMYST as a novel treatment option that can help ...

Shares of Milestone Pharmaceuticals Inc. (MIST) traded 60% lower on Friday after the Food and Drug Administration (FDA) did ...

Milestone Pharmaceuticals said on Friday the U.S. health regulator had declined to approve its nasal spray to treat a type of heart condition and had called for an inspection of the facility that ...